Literature DB >> 11607824

Biology of EWS/ETS fusions in Ewing's family tumors.

A Arvand1, C T Denny.   

Abstract

Tumor-associated chromosomal translocations lead to the formation of chimeric fusions between the EWS gene and one of five different ETS transcription factors in Ewing's family tumors (EFTs). The resultant EWS/ETS proteins promote oncogenesis in a dominant fashion in model systems and are necessary for continued growth of EFT cell lines. EWS belongs to a family of genes that encode proteins that may serve as adapters between the RNA polymerase II complex and RNA splicing factors. EWS/ETS fusions have biochemical characteristics of aberrant transcription factors and appear to promote abnormal cellular growth by transcriptionally modulating a network of target genes. Early evidence suggests that EWS/ETS proteins may also impact gene expression through alteration in RNA processing. Elucidation of EWS/ETS target gene networks in the context of other signaling pathways will hopefully lead to biology based therapeutic strategies for EFT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11607824     DOI: 10.1038/sj.onc.1204598

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  98 in total

1.  PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins.

Authors:  Benjamin Deneen; Scott M Welford; Thu Ho; Felicia Hernandez; Irwin Kurland; Christopher T Denny
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

2.  EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Authors:  Alexandre Prieur; Franck Tirode; Pinchas Cohen; Olivier Delattre
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 3.  Targeted therapy in bone and soft tissue sarcoma in children and adolescents.

Authors:  Patrick A Thompson; Murali Chintagumpala
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 4.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

5.  A practical approach to the clinical diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour and other small round cell tumours sharing EWS rearrangement using new fluorescence in situ hybridisation probes for EWSR1 on formalin fixed, paraffin wax embedded tissue.

Authors:  U Yamaguchi; T Hasegawa; Y Morimoto; U Tateishi; M Endo; F Nakatani; A Kawai; H Chuman; Y Beppu; M Endo; H Kurotaki; K Furuta
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

6.  Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins.

Authors:  Sungeun Kim; Christopher T Denny; Ron Wisdom
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

7.  Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.

Authors:  Yoshitaka Miyagawa; Hajime Okita; Hideki Nakaijima; Yasuomi Horiuchi; Ban Sato; Tomoko Taguchi; Masashi Toyoda; Yohko U Katagiri; Junichiro Fujimoto; Jun-Ichi Hata; Akihiro Umezawa; Nobutaka Kiyokawa
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

8.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 9.  Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals.

Authors:  Barbara Stecca; Ariel Ruiz i Altaba
Journal:  J Mol Cell Biol       Date:  2010-01-17       Impact factor: 6.216

Review 10.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.